David Gerber, M.D. , is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology/Oncology. He serves as Co-Director of the Experimental Therapeutics Program.
Originally from Chicago, Dr. Gerber holds a bachelor's degree in history from Yale University in New Haven, Connecticut, where he graduated cum laude. He earned his medical degree at Cornell University Medical College in New York, and completed his internship and residency in internal medicine at UT Southwestern, where he served as Chief Resident. He then received advanced training through a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore.
Board certified in internal medicine and medical oncology, Dr. Gerber joined the UT Southwestern faculty in 2007.
He is active in research related to lung cancer, including clinical trials. His research has generated more than 100 publications that he has authored or co-authored, including articles, abstracts, book chapters, book reviews, and invited manuscripts. His studies have contributed to invitations to lecture both nationally and internationally.
He serves on a number of committees at UT Southwestern, and he is an active participant on the American Society of Clinical Oncology’s Lung Cancer Education Committee and the International Association for the Study of Lung Cancer’s Career Development Committee. He also serves on the editorial board of the Journal of Clinical Oncology.
Dr. Gerber holds memberships in several professional organizations, and he has been honored with numerous awards, including being named a Best Doctor by D Magazine in 2018, 2020, 2021, and 2022.
- Medical School
- Weill Cornell Graduate School of Medical Science (2000)
- UT Southwestern Medical Center (2004), Internal Medicine
- Johns Hopkins Hospital (2007), Medical Oncology
- Lung Cancer, Clinical and Translational Research
- Oncology Outcomes
- Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
- Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR Ann. Oncol. 2018 May
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
- Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ Lung Cancer 2018 Mar 117 44-49
- How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
- Khan SA, Pruitt SL, Xuan L, Makris U, Gerber DE Lung Cancer 2018 Jan 115 97-102
- Cancer Center Clinic and Research Team Perceptions of Identity and Interactions.
- Reimer T, Lee SJC, Garcia S, Gill M, Duncan T, Williams EL, Gerber DE J Oncol Pract 2017 Oct JOP2017024349
- Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines.
- Ning N, Yan J, Dietrich MF, Xie XJ, Gerber DE J Oncol Pract 2017 Oct JOP2017024299
- Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity.
- Garcia S, Bisen A, Yan J, Xie XJ, Ramalingam S, Schiller JH, Johnson DH, Gerber DE J Thorac Oncol 2017 Jul
- Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options.
- Khan SA, Pruitt SL, Xuan L, Gerber DE JAMA Oncol 2016 Jun
- Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
- Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH Lung Cancer 2015 Oct
- Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.
- Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE J. Natl. Cancer Inst. 2015 Apr 107 4
- Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.
- Gerber DE, Hao G, Watkins L, Stafford JH, Anderson J, Holbein B, Öz OK, Mathews D, Thorpe PE, Hassan G, Kumar A, Brekken RA, Sun X Am J Nucl Med Mol Imaging 2015 5 5 493-503
Targeted Therapies for Non-Small Cell Lung Cancer
David E. Gerber (2011). Oxford University Press
Apar K. Ganti, David E. Gerber (Ed.) (2014). Oxford University Press
Honors & Awards
- Exceptional Research in Navigation Award
Academy of Oncology Nurse & Patient Navigators (2018)
- Top Doctors
Castle Connolly (2015-2022)
- Best Doctors in Dallas
D Magazine (2011-2022)
- Clinical Investigator Team Leadership Award
National Cancer Institute (2011)
- Career Development Award
American Society of Clinical Oncology (2009)
- George G. Reader Prize in Public Health
Cornell University (2000)
- Jay Lawrence Award for Proficiency in Infectious Diseases
Cornell University (2000)
- William Osler Medal, Honorable Mention
American Association for the History of Medicine (1999)
- American Society of Clinical Oncology
- Dallas County Medical Society
- Eastern Cooperative Oncology Group
- International Association for the Study of Lung Cancer
- National Lung Cancer Partnership/Free to Breathe
- Texas Medical Association